Your browser doesn't support javascript.
loading
Systemic silencing of PHD2 causes reversible immune regulatory dysfunction.
Yamamoto, Atsushi; Hester, Joanna; Macklin, Philip S; Kawai, Kento; Uchiyama, Masateru; Biggs, Daniel; Bishop, Tammie; Bull, Katherine; Cheng, Xiaotong; Cawthorne, Eleanor; Coleman, Mathew L; Crockford, Tanya L; Davies, Ben; Dow, Lukas E; Goldin, Rob; Kranc, Kamil; Kudo, Hiromi; Lawson, Hannah; McAuliffe, James; Milward, Kate; Scudamore, Cheryl L; Soilleux, Elizabeth; Issa, Fadi; Ratcliffe, Peter J; Pugh, Chris W.
Affiliation
  • Yamamoto A; Nuffield Department of Medicine Research Building, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Hester J; Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.
  • Macklin PS; Nuffield Department of Medicine Research Building, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Kawai K; Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.
  • Uchiyama M; Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.
  • Biggs D; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
  • Bishop T; Nuffield Department of Medicine Research Building, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Bull K; Henry Wellcome Building for Molecular Physiology, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Cheng X; Nuffield Department of Medicine Research Building, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Cawthorne E; Henry Wellcome Building for Molecular Physiology, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Coleman ML; Henry Wellcome Building for Molecular Physiology, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Crockford TL; Henry Wellcome Building for Molecular Physiology, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Davies B; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.
  • Dow LE; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York, USA.
  • Goldin R; Department of Cellular Pathology, Imperial College London, London, United Kingdom.
  • Kranc K; MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom.
  • Kudo H; Department of Cellular Pathology, Imperial College London, London, United Kingdom.
  • Lawson H; MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, United Kingdom.
  • McAuliffe J; Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Milward K; Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.
  • Scudamore CL; Veterinary Pathology, MRC Harwell, Mary Lyon Centre, Harwell Campus, Oxford, United Kingdom.
  • Soilleux E; Department of Pathology, School of Biological Sciences, University of Cambridge, Cambridge, United Kingdom.
  • Issa F; Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.
  • Ratcliffe PJ; Nuffield Department of Medicine Research Building, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Pugh CW; Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
J Clin Invest ; 129(9): 3640-3656, 2019 06 04.
Article in En | MEDLINE | ID: mdl-31162141
Physiological effects of cellular hypoxia are sensed by prolyl hydroxylase (PHD) enzymes which regulate HIFs. Genetic interventions on HIF/PHD pathways reveal multiple phenotypes that extend the known biology of hypoxia. Recent studies unexpectedly implicate HIF in aspects of multiple immune and inflammatory pathways. However such studies are often limited by systemic lethal effects and/or use tissue-specific recombination systems, which are inherently irreversible, un-physiologically restricted and difficult to time. To study these processes better we developed recombinant mice which express tetracycline-regulated shRNAs broadly targeting the main components of the HIF/PHD pathway, permitting timed bi-directional intervention. We have shown that stabilization of HIF levels in adult mice through PHD2 enzyme silencing by RNA interference, or inducible recombination of floxed alleles, results in multi-lineage leukocytosis and features of autoimmunity. This phenotype was rapidly normalized on re-establishment of the hypoxia-sensing machinery when shRNA expression was discontinued. In both situations these effects were mediated principally through the Hif2a isoform. Assessment of cells bearing regulatory T cell markers from these mice revealed defective function and pro-inflammatory effects in vivo. We believe our findings have shown a new role for the PHD2/Hif2a couple in the reversible regulation of T cell and immune activity.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Signal Transduction / T-Lymphocytes, Regulatory / RNA Interference / Hypoxia-Inducible Factor-Proline Dioxygenases Type of study: Etiology_studies / Prognostic_studies Limits: Animals Language: En Journal: J Clin Invest Year: 2019 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Signal Transduction / T-Lymphocytes, Regulatory / RNA Interference / Hypoxia-Inducible Factor-Proline Dioxygenases Type of study: Etiology_studies / Prognostic_studies Limits: Animals Language: En Journal: J Clin Invest Year: 2019 Document type: Article